Australian Operations
Include All CSL Behring Country Sites


Human coagulation factor VIII / von Willebrand factor concentrate (FVIII/VWF concentrate), powder for injection

For more information about BIOSTATE, please visit the New Zealand Blood Service website.

For information about haemophilia care in New Zealand, visit the Haemophilia Foundation of New Zealand website.
For information on how to prepare BIOSTATE using the Mix2Vial™
BIOSTATE is a freeze-dried preparation of human coagulation factor VIII / von Willebrand factor complex concentrate. Factor VIII (FVIII) and von Willebrand factor (VWF) are essential proteins for normal blood clotting.

BIOSTATE is used to:
  • replace FVIII in people with haemophilia A, a bleeding disorder in which there are reduced levels of FVIII.
  • replace VWF in people with von Willebrand disorder, a bleeding disorder in which there are reduced levels of VWF.
People with low levels of FVIII or VWF may have difficulty forming blood clots, and these clots may take longer to form. Sometimes, people with low levels of FVIII or VWF may bleed spontaneously into their joints or muscles.

BIOSTATE is supplied as a freeze-dried powder which is dissolved with Water for Injections and then injected into a vein. Each vial of BIOSTATE is packaged with one vial of Water for Injections and a plastic Mix2Vial™ filter transfer set that is used to transfer the Water for Injections into the BIOSTATE vial.

BIOSTATE is only available with a doctor's prescription.

Data sheet
The data sheet contains information to ensure the safe and effective use of a medicine. This document is approved by Medsafe and is made available by CSL  for you if you are a:
a.qualified healthcare professional; or
b.person who has been prescribed this product, and who agrees to consult with your healthcare professional if you have any questions in relation to the Product Information.
PDF icon BIOSTATE Data Sheet (PDF, 0.188MB)

® Registered Trademark of CSL Limited
™ Mix2Vial is a trademark of West Pharmaceutical Services, Inc or a subsidiary thereof.

Date of preparation: September 2013